PMID- 17130903
OWN - NLM
STAT- MEDLINE
DCOM- 20070522
LR  - 20181201
IS  - 0818-9641 (Print)
IS  - 0818-9641 (Linking)
VI  - 85
IP  - 1
DP  - 2007 Jan
TI  - Upregulation of MIP-2 (CXCL2) expression by 15-deoxy-Delta(12,14)-prostaglandin 
      J(2) in mouse peritoneal macrophages.
PG  - 60-7
AB  - A peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, 
      15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), has been reported to 
      possess anti-inflammatory activity in activated monocytes/macrophages. In this 
      study, we investigated the effect of 15d-PGJ(2) on the lipopolysaccharide 
      (LPS)-induced expression of chemokine mRNAs, especially macrophage inhibitory 
      protein (MIP)-2 (CXCL2), in mouse peritoneal macrophages. The inhibitory actions 
      of the natural PPARgamma ligands, 15d-PGJ(2) and prostaglandin A1 (PGA1), on the 
      expression of RANTES (regulated upon activation, normal T expressed and secreted; 
      CCL5), MIP-1beta (CCL4), MIP-1alpha (CCL3), IFN-gamma-inducible protein 10 
      kilodaltons (IP-10; CXCL10) and monocyte chemoattractant protein-1 (MCP-1; CCL2) 
      mRNA in LPS-treated cells were stronger than those of the synthetic PPARgamma 
      ligands troglitazone and ciglitazone. However, 15d-PGJ(2) enhanced the expression 
      of LPS-induced MIP-2 (CXCL2) mRNA. A specific PPARgamma antagonist (GW9662) had 
      no effect on the inhibitory action of 15d-PGJ(2) and PGA1 in LPS-induced 
      chemokine mRNA expression and on the synergistic action of 15d-PGJ(2) in 
      LPS-induced MIP-2 (CXCL2) expression. Moreover, LPS itself reduced the expression 
      of PPARgamma. Although the synergistic effect of 15d-PGJ(2) on LPS-induced MIP-2 
      (CXCL2) mRNA expression was remarkable, the production of MIP-2 (CXCL2) in cells 
      treated with 15d-PGJ(2) and LPS did not increase compared to the production in 
      cells treated with LPS alone. The synergistic action of 15d-PGJ(2) on LPS-induced 
      MIP-2 (CXCL2) mRNA expression was dependent on the activation of nuclear 
      factor-kappaB (NF-kappaB), and 15d-PGJ(2) increased the phosphorylation of p38 
      and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in cells 
      stimulated with LPS. These results suggest that the synergistic effect of 
      15d-PGJ(2) on LPS-induced MIP-2 (CXCL2) expression is PPARgamma-independent, and 
      is mediated by the p38 and SAPK/JNK pathway in mitogen-activated protein kinase 
      signaling pathways, which activates NF-kappaB. Our data may give more insights 
      into the different mechanisms contrary to the anti-inflammatory effect of 
      15d-PGJ(2) on the expression of chemokine genes.
FAU - Kim, Hyo Y
AU  - Kim HY
AD  - Department of Microbiology and Aging-associated Vascular Disease Research Center, 
      College of Medicine, Yeungnam University, Daegu, Korea.
FAU - Kim, Hee S
AU  - Kim HS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061128
PL  - United States
TA  - Immunol Cell Biol
JT  - Immunology and cell biology
JID - 8706300
RN  - 0 (15-deoxy-delta(12,14)-prostaglandin J2)
RN  - 0 (CXCL2 protein, human)
RN  - 0 (Chemokine CXCL2)
RN  - 0 (Chemokines)
RN  - 0 (Chemokines, CXC)
RN  - 0 (Chromans)
RN  - 0 (Immunologic Factors)
RN  - 0 (Ligands)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (PPAR gamma)
RN  - 0 (Prostaglandins A)
RN  - 0 (RNA, Messenger)
RN  - 0 (Thiazolidinediones)
RN  - I66ZZ0ZN0E (Troglitazone)
RN  - RXY07S6CZ2 (Prostaglandin D2)
RN  - U8QXS1WU8G (ciglitazone)
RN  - VYR271N44P (prostaglandin A1)
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - Chemokine CXCL2
MH  - Chemokines/metabolism
MH  - Chemokines, CXC/*metabolism
MH  - Chromans/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Immunologic Factors/*pharmacology
MH  - Ligands
MH  - Lipopolysaccharides/pharmacology
MH  - Macrophages, Peritoneal/drug effects/*metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - PPAR gamma/metabolism
MH  - Prostaglandin D2/*analogs & derivatives/pharmacology
MH  - Prostaglandins A/pharmacology
MH  - RNA, Messenger/metabolism
MH  - Thiazolidinediones/pharmacology
MH  - Troglitazone
MH  - *Up-Regulation
EDAT- 2006/11/30 09:00
MHDA- 2007/05/23 09:00
CRDT- 2006/11/30 09:00
PHST- 2006/11/30 09:00 [pubmed]
PHST- 2007/05/23 09:00 [medline]
PHST- 2006/11/30 09:00 [entrez]
AID - 7100001 [pii]
AID - 10.1038/sj.icb.7100001 [doi]
PST - ppublish
SO  - Immunol Cell Biol. 2007 Jan;85(1):60-7. doi: 10.1038/sj.icb.7100001. Epub 2006 
      Nov 28.